Sanofi gets positive results for eczema treatment – this time in young children

A new phase III study of Sanofi's Dupixent in very young children with moderate to severe atopic dermatitis has generated positive results.

Photo: CHARLES PLATIAU/Reuters / X00217

Last year, Sanofi received authorization to market Dupixent as a treatment for childhood eczema to patients aged 6 and 11. Now, it seems that the company is setting its sights on even younger children.

In this vein, the firm recently published results from a new phase III study of the drug, where it was tested on young children aged 6 months to 5 years with moderate to severe eczema, also known as atopic dermatitis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs